-

LivaNova Comments on Decision by Court of Appeal of Milan

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commented on the decision delivered today by the Court of Appeal of Milan (CoA) for LivaNova to pay damages in the amount of €453 million (approximately U.S. $519 million) as a result of a civil action where the CoA declared LivaNova (formed through a merger with Sorin) jointly liable with SNIA (a former parent company of Sorin) for environmental liabilities incurred by SNIA’s other subsidiaries. LivaNova strongly disagrees with the decision and will vigorously pursue all available remedies, including an appeal to the Italian Supreme Court. LivaNova filed an appeal over two years ago with the Italian Supreme Court regarding the CoA’s previous decision on joint liability, though the damages decision may not be stayed pending resolution of the appeal on joint liability by the Italian Supreme Court.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding legal proceedings, court judgments and actions in response to such litigation. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Summary
LivaNova commented on the decision delivered today by the Court of Appeal of Milan for LivaNova to pay damages as a result of a civil action.
Release Versions

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

More News From LivaNova PLC

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be...

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F...

Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company’s OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova’s aura6000™ System for the treatment of mod...
Back to Newsroom